Cytokinetics (CYTK) Gains from Sales and Divestitures (2016 - 2017)
Historic Gains from Sales and Divestitures for Cytokinetics (CYTK) over the last 6 years, with Q4 2017 value amounting to $171250.0.
- Cytokinetics' Gains from Sales and Divestitures rose 27431.69% to $171250.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $171250.0, marking a year-over-year increase of 27431.69%. This contributed to the annual value of $171250.0 for FY2017, which is 27431.69% up from last year.
- Cytokinetics' Gains from Sales and Divestitures amounted to $171250.0 in Q4 2017, which was up 27431.69% from $45750.0 recorded in Q4 2016.
- In the past 5 years, Cytokinetics' Gains from Sales and Divestitures ranged from a high of $211897.0 in Q3 2013 and a low of $20833.0 during Q4 2014
- In the last 5 years, Cytokinetics' Gains from Sales and Divestitures had a median value of $108500.0 in 2016 and averaged $117284.2.
- As far as peak fluctuations go, Cytokinetics' Gains from Sales and Divestitures plummeted by 9016.83% in 2014, and later surged by 27431.69% in 2017.
- Cytokinetics' Gains from Sales and Divestitures (Quarter) stood at $211897.0 in 2013, then tumbled by 90.17% to $20833.0 in 2014, then surged by 101.98% to $42078.0 in 2015, then increased by 8.73% to $45750.0 in 2016, then surged by 274.32% to $171250.0 in 2017.
- Its last three reported values are $171250.0 in Q4 2017, $45750.0 for Q4 2016, and $42078.0 during Q4 2015.